Skip to content

Peginterferon alfa-2a

Pegasys (peginterferon alfa-2a) is a protein pharmaceutical. Peginterferon alfa-2a was first approved as Pegasys on 2002-06-20. It is used to treat brain neoplasms, chronic hepatitis b, chronic hepatitis c, colorectal neoplasms, and cryoglobulinemia amongst others in the USA. It has been approved in Europe to treat chronic hepatitis b and chronic hepatitis c.
Trade Name Pegasys
Common Name Peginterferon alfa-2a
Indication brain neoplasms, chronic hepatitis b, chronic hepatitis c, colorectal neoplasms, cryoglobulinemia, essential thrombocythemia, hairy cell leukemia, hemangioma, hepatitis d, hepatocellular carcinoma, hypereosinophilic syndrome, ileal neoplasms, kaposi sarcoma, macular degeneration, melanoma, multiple myeloma, mycosis fungoides, renal cell carcinoma, sezary syndrome, skin neoplasms, skin ulcer, thrombocytopenia, warts
Drug Class Pegylated compounds
Peginterferon alfa-2a
Get full access now